RayKnowChina Research Map
Shortlist0

Shanghai Jiao Tong University School of Medicine

上海交通大学医学院

ShanghaiUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.9%Leads under 1 in 100 of China's research papers on NPC

Led 22 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
2
Research papers it led
22
Trials it led
3
Share of China's trials
0.5%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 222025
ThemesImaging & AIRadiotherapy techniqueInduction / concurrent chemotherapy

Hospitals counted here

  1. Shanghai Ninth People's Hospital6
  2. Shanghai General Hospital5
  3. Shanghai Sixth People's Hospital3
  4. Renji Hospital2
  5. Ruijin Hospital Counted in the group total2
  6. Songjiang Hospital, Affiliated To Shanghai Jiao Tong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Combination of pan-immune-inflammation value and frailty index predicts the outcomes of elderly nasopharyngeal carcinoma treated by concurrent chemoradiotherapy.2025Future oncology (London, England)
  2. Artificial Intelligence-Powered Spatial Analysis of the Tumor Microenvironment in Pulmonary Lymphoepithelial Carcinoma.2025Laboratory investigation; a journal of technical methods and pathology
  3. Prognostic significance of platelet‑to‑albumin ratio in patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: a retrospective study of 858 cases.2024BMC cancerFree full text
  4. Regenerating gene IA predicts radiosensitivity and survival in nasopharyngeal carcinoma.2022Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  5. Prognostic significance of MRI-based late-course tumor volume in locoregionally advanced nasopharyngeal carcinoma.2022Radiation oncology (London, England)Free full text
Trials on ClinicalTrials.gov6
  1. CD70-targeted immunoPET Imaging of Malignant CancersRecruitingNCT06852638Lead sponsorPhase 2Start 2024-12
  2. Trop2-targeted immunoPET Imaging of Solid TumorsRecruitingNCT06851663Lead sponsorPhase 2/Phase 3Start 2024-12
  3. Adjuvant vs Surgery Only in Early-stage Recurrent NPCRecruitingNCT06228079Study sitePhase 3Start 2024-06
  4. Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPCRecruitingNCT06235203Study sitePhase 3Start 2024-07
  5. Effect of Oral Supplements on the Nutritional Status of Locally Advanced Nasopharyngeal Carcinoma PatientsCompletedNCT02776124Lead sponsorPhase 2Start 2014-06
  6. Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)TerminatedNCT05721222Study sitePhase 1/Phase 2Start 2023-03

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
2.8%Leads about 1 in 36 of China's research papers on ESCC ▲ from 1.7%

Led 82 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
14
Research papers it led
82
Trials it led
28
Share of China's trials
4.9%
Share of the world's papers
1.9%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025
ThemesNeoadjuvant & combined treatmentRadiotherapyImmunotherapy

Hospitals counted here

  1. Shanghai Chest Hospital40
  2. Ruijin Hospital22
  3. Renji Hospital8
  4. Shanghai Ninth People's Hospital4
  5. Shanghai General Hospital3
  6. Xinhua Hospital Counted in the group total2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Postoperative tumor bed radiation versus T-shaped field radiation in the treatment of locally advanced thoracic esophageal squamous cell carcinoma: a phase IIb multicenter randomized controlled trial.2024BMC medicineRCTFree full text
  2. Impact of Lymph Node Dissection on Survival After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.2023Annals of surgeryRCT
  3. Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 St2022BMC cancerRCTFree full text
  4. Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma: Early Results of a Multicenter Randomized Controlled Trial: the RAMIE Trial.2022Annals of surgeryRCT
  5. Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2).2025Signal transduction and targeted therapyFree full text
Trials on ClinicalTrials.gov6
  1. Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCCNot yet recruitingNCT07769866Lead sponsorN/AStart 2026-09
  2. SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After ImmunotherapyNot yet recruitingNCT07524374Lead sponsorPhase 2Start 2026-03
  3. Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal CancerRecruitingNCT07811752Lead sponsorPhase 2Start 2026-07
  4. Infiltration Pattern of Locally Advanced ESCCEnrolling by invitationNCT07567716Lead sponsorStart 2025-10
  5. Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCCNot yet recruitingNCT06861894Lead sponsorPhase 2Start 2025-07
  6. RAE Versus MIE in Patients With Esophageal Cancer After Neoadjuvant TherapyNot yet recruitingNCT06012214Lead sponsorN/AStart 2024-01

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.8%Leads about 1 in 57 of China's research papers on HCC ▼ from 2.8%

Led 260 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
9
Research papers it led
260
Trials it led
25
Share of China's trials
1.7%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Renji Hospital104
  2. Shanghai General Hospital36
  3. Ruijin Hospital35
  4. Shanghai Sixth People's Hospital27
  5. Xinhua Hospital21
  6. Shanghai Ninth People's Hospital Counted in the group total10

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Interim analysis of the PARADISE study: Benefits of add-on peginterferon-α in NA-treated patients with CHB.2024Antiviral researchRCT
  2. Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer.2025Cancer cell
  3. Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial.2024Signal transduction and targeted therapyFree full text
  4. Novel molecular mechanisms of immune evasion in hepatocellular carcinoma: NSUN2-mediated increase of SOAT2 RNA methylation.2025Cancer communications (London, England)Free full text
  5. Hepatocellular carcinoma: signaling pathways and therapeutic advances.2025Signal transduction and targeted therapyFree full text
Trials on ClinicalTrials.gov6
  1. Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)RecruitingNCT07331883Lead sponsorPhase 2Start 2025-11
  2. FGF19 Overexpression Combination Unified Study in HCC-19RecruitingNCT06978933Lead sponsorPhase 2Start 2025-04
  3. HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCCNot yet recruitingNCT07045558Lead sponsorStart 2025-08
  4. DEB-TACE Prior to Liver Transplantation in the Treatment of HCCRecruitingNCT06353126Lead sponsorPhase 4Start 2024-10
  5. Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular CarcinomaRecruitingNCT06519578Lead sponsorN/AStart 2024-08
  6. Clinical Study of SN301A Injection in the Treatment of Hepatocellular CarcinomaRecruitingNCT06652243Lead sponsorEarly phase 1Start 2024-11

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
2.8%Leads about 1 in 35 of China's research papers on Stomach cancer ▼ from 4.1%

Led 276 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
19
Research papers it led
276
Trials it led
61
Share of China's trials
4.2%
Share of the world's papers
1.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 222025
ThemesPeritoneal spread & advanced diseaseImaging & AIChemotherapy & combined treatment

Hospitals counted here

  1. Ruijin Hospital96
  2. Renji Hospital65
  3. Shanghai General Hospital27
  4. Xinhua Hospital24
  5. Shanghai Ninth People's Hospital22
  6. Shanghai Sixth People's Hospital21

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05).2025Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCTFree full text
  2. Long-term outcomes and quality of life of laparoscopic-assisted pylorus-preserving gastrectomy compared to laparoscopic-assisted distal gastrectomy with billroth I anastomosis for early gastric cancer(pT1N0M0): A Randomi2025American journal of surgeryRCT
  3. Study on the therapeutic effect of sintilimab combined with modified DCF regimen on advanced gastric cancer and its impact on Th1/Th2 immune balance.2024Anti-cancer drugsRCTFree full text
  4. The effect of self-designed metabolic equivalent exercises on cancer-related fatigue in patients with gastric cancer: A randomized controlled trial.2024Cancer medicineRCTFree full text
  5. Effectiveness and safety of Moluodan in the treatment of precancerous lesions of gastric cancer: A randomized clinical trial.2024Journal of digestive diseasesRCT
Trials on ClinicalTrials.gov6
  1. GK01 Cell Therapy in Gastric Cancer With Peritoneal MetastasisNot yet recruitingNCT07923396Lead sponsorPhase 1Start 2026-11
  2. LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory StudyRecruitingNCT07556640Lead sponsorPhase 2Start 2026-04
  3. Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET ImagingNot yet recruitingNCT07554742Lead sponsorStart 2026-04
  4. Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric CancerNot yet recruitingNCT06888037Lead sponsorPhase 2Start 2025-03
  5. Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction CancerRecruitingNCT07867392Lead sponsorPhase 2Start 2025-02
  6. Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric CancerRecruitingNCT07026149Lead sponsorPhase 2Start 2025-06

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
13.6%Leads about 1 in 7 of China's research papers on Hepatoblastoma ▲ from 10.6%

Led 21 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
1
Research papers it led
21
Trials it led
6
Share of China's trials
60.0%
Share of the world's papers
4.7%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 4420242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shanghai Children's Medical Center17
  2. Renji Hospital3
  3. Xinhua Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Clinical Characteristics and Outcomes of Neonatal Hepatoblastoma: A Single Center Study.2024Journal of pediatric surgery
  2. PIVKA-II combined with alpha-fetoprotein for the diagnostic value of hepatic tumors in children: a multicenter, prospective observational study.2024Hepatology international
  3. A multicenter prospective study on the management of hepatoblastoma in children: a report from the Chinese Children's Cancer Group.2024World journal of pediatrics : WJP
  4. Pediatric Hepatoblastoma After Neoadjuvant Chemotherapy: Diagnostic Performance of MR in Staging POSTTEXT and Vascular Involvement.2024Journal of magnetic resonance imaging : JMRI
  5. TCF3 activates super-enhancer-driven TRIB2 overexpression to suppress ferroptosis and promote hepatoblastoma proliferation.2025Journal of experimental & clinical cancer research : CR
Trials on ClinicalTrials.gov6
  1. A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT StrategyRecruitingNCT04478292Lead sponsorPhase 3Start 2021-03
  2. Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large ModelsCompletedNCT06822842Lead sponsorStart 2025-01
  3. Evaluation of Lung Metastases Based on Ultrashort Echo Time MRICompletedNCT05763173Lead sponsorStart 2023-01
  4. Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After ChemotherapyStatus unknownNCT05322187Lead sponsorPhase 2/Phase 3Start 2022-04
  5. PIVKA-II Combined With Alpha-Fetoprotein for Diagnostic and Prognostic Value of Hepatic Tumors in InfantsCompletedNCT03645655Lead sponsorStart 2018-10
  6. G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorStatus unknownNCT02933333Lead sponsorPhase 4Start 2016-09

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
12.0%Leads about 1 in 8 of China's research papers on Retinoblastoma ▲ from 3.1%

Led 36 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
36
Trials it led
1
Share of China's trials
7.7%
Share of the world's papers
3.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 442025

Hospitals counted here

  1. Shanghai Ninth People's Hospital29
  2. Xinhua Hospital5
  3. Renji Hospital1
  4. Shanghai General Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Chordoma

脊索瘤
5.7%Leads about 1 in 18 of China's research papers on Chordoma New since 2021

Led 6 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.8%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.1%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 1120242025: 222025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shanghai General Hospital5
  2. Renji Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
4.3%Leads about 1 in 23 of China's research papers on Osteosarcoma ▼ from 6.9%

Led 98 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
1
Research papers it led
98
Trials it led
7
Share of China's trials
12.1%
Share of the world's papers
1.9%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 332025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shanghai Sixth People's Hospital35
  2. Shanghai General Hospital24
  3. Shanghai Ninth People's Hospital16
  4. Ruijin Hospital13
  5. Xinhua Hospital4
  6. Renji Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Osteitis in long bones of SAPHO syndrome mimicking osteosarcoma.2024Rheumatology (Oxford, England)
  2. Etoposide activates CD8+ T cell anti-tumor immunity in osteosarcoma through MHC I upregulation via tumor-secreted IL-33 mediated signaling.2025Journal for immunotherapy of cancer
  3. Enhanced antitumor immunity of VNP20009-CCL2-CXCL9 via the cGAS/STING axis in osteosarcoma lung metastasis.2025Journal for immunotherapy of cancer
  4. Stereotactic Body Radiation Therapy Augmented Checkpoint Inhibitor Immunotherapy Response in Heavily Pretreated Metastatic Osteosarcoma.2026International journal of radiation oncology, biology, physics
  5. Prognostic factors of head and neck osteosarcoma: A 10-year retrospective study from a single institute.2025Oral oncology
Trials on ClinicalTrials.gov6
  1. Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical TrialRecruitingNCT06114225Lead sponsorPhase 2Start 2023-06
  2. KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)RecruitingNCT07596693Study sitePhase 1Start 2025-12
  3. ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasRecruitingNCT05830123Study sitePhase 2Start 2023-06
  4. Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma PatientsNot yet recruitingNCT07142863Lead sponsorPhase 2Start 2025-08
  5. Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in OsteosarcomaCompletedNCT06562673Lead sponsorPhase 1/Phase 2Start 2024-12
  6. A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue TumorsStatus unknownNCT06171282Lead sponsorEarly phase 1Start 2023-07

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
3.4%Leads about 1 in 29 of China's research papers on Gastrointestinal stromal tumour ▼ from 4.7%

Led 18 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
18
Trials it led
3
Share of China's trials
4.0%
Share of the world's papers
1.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 4420242025: 112025

Hospitals counted here

  1. Renji Hospital10
  2. Shanghai Ninth People's Hospital4
  3. Ruijin Hospital2
  4. Shanghai General Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Development and validation of a machine-learning-based pathomics nomogram for predicting recurrence of localized primary gastrointestinal stromal tumors after complete surgical resection: A retrospective multicenter stud2025Cancer
  2. Identification of D842V mutation in gastrointestinal stromal tumors based on CT radiomics: a multi-center study.2024Cancer imaging : the official publication of the International Cancer Imaging Society
  3. Long-term survival outcomes of endoscopic therapy vs. surgical resection in patients with cardia gastrointestinal stromal tumor.2024PloS oneFree full text
  4. Adult Female Patient with Untreated Truncus Arteriosus Type I and Torsion of Small Bowel Gastrointestinal Stromal Tumor: A Rare Case Report.2024The American journal of case reports
  5. The impact of gender on survival outcomes in patients with small intestinal stromal tumors: a comprehensive analysis using the SEER database.2024Surgical endoscopy
Trials on ClinicalTrials.gov6
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  2. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)RecruitingNCT04924075Study sitePhase 2Start 2021-08
  3. Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib TherapyStatus unknownNCT05132738Lead sponsorN/AStart 2021-08
  4. Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of StomachStatus unknownNCT05197933Lead sponsorN/AStart 2020-10
  5. Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal TumorStatus unknownNCT02931981Lead sponsorStart 2016-10
  6. A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)CompletedNCT04282980Study sitePhase 2Start 2020-04

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
4.3%Leads about 1 in 23 of China's research papers on Neuroblastoma ▼ from 5.8%

Led 49 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
49
Trials it led
6
Share of China's trials
14.3%
Share of the world's papers
1.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 4420242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Xinhua Hospital17
  2. Shanghai Children's Medical Center11
  3. Shanghai Children's Hospital5
  4. Shanghai Sixth People's Hospital4
  5. Renji Hospital2
  6. Ruijin Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. C-reactive protein-to-lymphocyte ratio and hemoglobin-to-red cell distribution width ratio as effective prognostic predictors in pediatric patients with neuroblastoma.2025European journal of pediatrics
  2. Neuroblastoma with high ASPM reveals pronounced heterogeneity and poor prognosis.2024BMC cancer
  3. Tracking changes in image-defined risk factors during neoadjuvant chemotherapy and their predictive value for surgical outcomes based on the International Neuroblastoma Surgical Report Form.2024Pediatric blood & cancer
  4. The prognostic role of 18F-FDG PET/CT-based response evaluation in children with stage 4 neuroblastoma.2024European radiology
  5. Analysis of the incidence, characteristics, and risk factors of complications during induction chemotherapy in children with high-risk neuroblastoma.2024European journal of pediatrics
Trials on ClinicalTrials.gov6
  1. Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in ChinaNot yet recruitingNCT06873672Lead sponsorStart 2025-04
  2. Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large ModelsCompletedNCT06822842Lead sponsorStart 2025-01
  3. Risk Model for Metastasis Detection of NeuroblastomaEnrolling by invitationNCT06703944Lead sponsorStart 2024-12
  4. Study on Sintilimab in Stage IV High Risk NeuroblastomaStatus unknownNCT04412408Lead sponsorEarly phase 1Start 2020-09
  5. G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorStatus unknownNCT02933333Lead sponsorPhase 4Start 2016-09
  6. Anti-angiogenetic Therapy With Radiotherapy for Pediatric NeuroblastomaStatus unknownNCT02615106Lead sponsorPhase 2Start 2015-11

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
1.8%Leads about 1 in 54 of China's research papers on Ewing sarcoma ▼ from 3.6%

Led 3 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. Shanghai Children's Hospital1
  2. Shanghai Sixth People's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
3.2%Leads about 1 in 32 of China's research papers on Myeloma ▲ from 1.8%

Led 53 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
2
Research papers it led
53
Trials it led
9
Share of China's trials
1.8%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 222025
ThemesDiagnosis, MRD & riskCAR-T & cell therapyDrug combinations

Hospitals counted here

  1. Renji Hospital24
  2. Ruijin Hospital22
  3. Xinhua Hospital2
  4. Shanghai General Hospital2
  5. Songjiang Hospital, Shanghai Jiao Tong University1
  6. Shanghai Sixth People's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma.2025Scientific reportsRCTFree full text
  2. Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).2023Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  3. Dual roles of IRE1α inhibition in reversing mitochondrial ROS-induced CD8+ T-cell senescence and exerting direct antitumor effects in multiple myeloma.2025Journal for immunotherapy of cancerFree full text
  4. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion.2024Journal for immunotherapy of cancerFree full text
  5. Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity.2023Signal transduction and targeted therapyFree full text
Trials on ClinicalTrials.gov6
  1. Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F InjectionEnrolling by invitationNCT07833046Lead sponsorStart 2026-11
  2. Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple MyelomaNot yet recruitingNCT06594211Lead sponsorN/AStart 2024-10
  3. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  4. A Study of IMV102 in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07493135Study siteEarly phase 1Start 2026-04
  5. Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood CancersRecruitingNCT07914556Study sitePhase 1Start 2026-09
  6. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
8.9%Leads about 1 in 11 of China's research papers on B-ALL ▲ from 3.9%

Led 20 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
5
Research papers it led
20
Trials it led
9
Share of China's trials
3.6%
Share of the world's papers
1.8%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025
ThemesChildrenPhiladelphia chromosome & geneticsAntibody & targeted drugs

Hospitals counted here

  1. Ruijin Hospital11
  2. Shanghai Children's Medical Center8
  3. Shanghai Children's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Blinatumomab demonstrates MRD eradication in MRD-positive/chemotherapy-delayed pediatric B-ALL and high response in relapsed/refractory cases: a multicenter cohort study.2025Frontiers in immunologyFree full text
  2. Differences in response to immunotherapy drugs including blinatumomab and inotuzumab ozogamicin in B-ALL patients.2025International journal of hematology
  3. Philadelphia chromosome-positive or Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with multilineage involvement in pediatric patients: a report of two cases and literature review.2025Pharmacogenetics and genomicsFree full text
  4. Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia/lymphoma following allogeneic hematopoietic cell transplantation.2024Blood cancer journalFree full text
  5. TCRαβ-depleted hematopoietic stem cell transplant and third-party CD45RA+ depleted adoptive cell therapy for treatment of post-transplant parvovirus B19 aplastic crisis.2024International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Trials on ClinicalTrials.gov6
  1. Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic LeukemiaRecruitingNCT07838714Lead sponsorPhase 1Start 2026-05
  2. BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia PatientsNot yet recruitingNCT07301138Lead sponsorPhase 2Start 2025-12
  3. Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute LeukemiaNot yet recruitingNCT07087847Lead sponsorN/AStart 2025-09
  4. Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic LeukemiaRecruitingNCT06607419Lead sponsorPhase 2/Phase 3Start 2024-05
  5. Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1RecruitingNCT06718244Lead sponsorPhase 2Start 2024-12
  6. Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALLNot yet recruitingNCT06641024Study sitePhase 1Start 2024-11

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
1.5%Leads about 1 in 68 of China's research papers on Aplastic anaemia ▼ from 2.5%

Led 6 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
1
Share of China's trials
1.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 1120242025: 112025
ThemesStem cell transplantChildrenImmunosuppressive treatment

Hospitals counted here

  1. Shanghai Children's Medical Center5
  2. Shanghai Ninth People's Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
2.0%Leads about 1 in 50 of China's research papers on HLH ▼ from 3.1%

Led 8 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 1120242025: 112025
ThemesDiagnosis & prognosisTreatment regimensLymphoma & cancer-related HLH

Hospitals counted here

  1. Renji Hospital3
  2. Ruijin Hospital2
  3. Shanghai Children's Medical Center Counted in the group total1
  4. Shanghai Sixth People's Hospital Counted in the group total1
  5. Shanghai Children's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. The role of blood cell morphology in understanding and diagnosing severe fever with thrombocytopenia syndrome (SFTS): Insights from a case report.2024MedicineFree full text
  2. Prognostic death factors in secondary hemophagocytic lymphohistiocytosis children with multiple organ dysfunction syndrome receiving continuous renal replacement therapy: A multicenter prospective nested case-control stu2022Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis TherapyFree full text
  3. Risk factors for secondary hemophagocytic lymphohistiocytosis in severe coronavirus disease 2019 adult patients.2021BMC infectious diseasesFree full text
  4. Gastric ulcer as the main complication in hemophagocytic lymphohistiocytosis: A case report.2021Journal of digestive diseases
  5. Ruxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome.2025BloodFree full text
Trials on ClinicalTrials.gov2
  1. A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])RecruitingNCT07208058Study sitePhase 3Start 2025-11
  2. A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))CompletedNCT07034209Study sitePhase 2Start 2023-04

PubMed searchClinicalTrials.gov

Beta thalassaemia

β 地中海贫血
2.6%Leads about 1 in 39 of China's research papers on Beta thalassaemia ▲ from 1.2%

Led 8 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.9%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 222025

Hospitals counted here

  1. Shanghai Children's Hospital4
  2. Child Health Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Modified lentiviral globin gene therapy for pediatric β0/β0 transfusion-dependent β-thalassemia: A single-center, single-arm pilot trial.2024Cell stem cell
  2. Carrier screening for multiple complex monogenic diseases using long-read sequencing: a population-based study of premarital couples in Shanghai.2025Human genomics
  3. Targeted long-read sequencing facilitates effective carrier screening for complex monogenic diseases including spinal muscular atrophy, α-/β-thalassemia, 21-hydroxylase deficiency, and fragile-X syndrome.2025Journal of translational medicine
  4. Gene Editing of the Endogenous Cryptic 3' Splice Site Corrects the RNA Splicing Defect in the β654-Thalassemia Mouse Model.2024Human gene therapy
  5. shRNA Targeting Lentiviral Vector Minus-Strand Product Improves the Viral Titer During Viral Packaging.2024Molecular biotechnology
Trials on ClinicalTrials.gov6
  1. A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia MajorRecruitingNCT06465550Study sitePhase 1Start 2024-01
  2. β-Thalassemia Treatment With KL003 Cell InjectionRecruitingNCT06280378Study sitePhase 1/Phase 2Start 2024-04
  3. A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia MajorNot yet recruitingNCT07489196Study sitePhase 2Start 2026-04
  4. A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia MajorCompletedNCT06291961Study sitePhase 1Start 2024-04
  5. Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemiaStatus unknownNCT05773729Study siteN/AStart 2023-09
  6. Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemiaStatus unknownNCT05776173Study siteN/AStart 2023-08

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
2.2%Leads about 1 in 45 of China's research papers on Haemophilia A ▼ from 6.0%

Led 6 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 0020242025: 222025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Ruijin Hospital5
  2. Shanghai Ninth People's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. A real-world pharmacovigilance analysis of the FDA adverse event reporting system database for emicizumab.2025Thrombosis research
  2. Single-cell sequencing on PBMCs from patients with HA and HB with inhibitors reveals different immune responses to FVIII and FIX.2025Blood advances
  3. Tandem and inverted duplications in haemophilia A: Breakpoint characterisation provides insight into possible rearrangement mechanisms.2023Haemophilia : the official journal of the World Federation of Hemophilia
  4. Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain.2022Frontiers of medicine
  5. Characteristics of the Thrombus Formation in Transgenic Mice with Platelet-Targeted Factor VIII Expression.2022Thrombosis and haemostasis
Trials on ClinicalTrials.gov6
  1. An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII DeficiencyRecruitingNCT07644832Study sitePhase 1/Phase 2Start 2024-05
  2. Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCompletedNCT06738485Study sitePhase 3Start 2025-01
  3. Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with InhibitorCompletedNCT06289166Study sitePhase 2Start 2024-03
  4. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12
  5. Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A ParticipantsCompletedNCT03315455Study sitePhase 3Start 2018-04
  6. Evaluate Efficacy and Safety of Recombinant Factor VIII (rFVIII)Treatment of Severe or Moderately Severe Hemophilia AStatus unknownNCT02930317Study sitePhase 3Start 2016-08

PubMed searchClinicalTrials.gov

Fanconi anaemia

范可尼贫血
4.4%Leads about 1 in 23 of China's research papers on Fanconi anaemia ▼ from 7.4%

Led 3 of 68 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Shanghai Children's Medical Center2
  2. Shanghai Ninth People's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
3.1%Leads about 1 in 32 of China's research papers on NMOSD

Led 15 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
1
Research papers it led
15
Trials it led
1
Share of China's trials
1.3%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 2220242025: 112025
ThemesAntibodies & diagnosisAcute attack treatmentImaging

Hospitals counted here

  1. Renji Hospital11
  2. Shanghai Sixth People's Hospital2
  3. Shanghai Chest Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
1.2%Leads about 1 in 82 of China's research papers on IgG4-RD ▼ from 2.5%

Led 3 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
1
Share of China's trials
2.3%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 2220242025: 002025
ThemesHead, eye socket & salivary glandsPancreas & bile ducts

Hospitals counted here

  1. Renji Hospital2
  2. Shanghai Ninth People's Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led3
  1. IL-33/ST2 enhances MMP-12 expression by macrophages to mediate inflammatory and immune response in IgG4-Related Ophthalmic Disease.2024Cytokine
  2. IgG4-related disease with duodenal bulb involvement.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  3. Interleukin-35 Promotes Th9 Cell Differentiation in IgG4-Related Disorders: Experimental Data and Review of the Literature.2021Clinical reviews in allergy & immunology
Trials on ClinicalTrials.gov3
  1. Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related DiseaseRecruitingNCT07061938Study sitePhase 1/Phase 2Start 2026-01
  2. Multicenter Observational Study of PSC and IgG4-SC in ChinaStatus unknownNCT05463445Lead sponsorStart 2022-07
  3. A Phase 3 Study of Obexelimab in Patients With IgG4-Related DiseaseActive, not recruitingNCT05662241Study sitePhase 3Start 2023-01

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
1.4%Leads about 1 in 71 of China's research papers on Myasthenia gravis

Led 7 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
1
Research papers it led
7
Trials it led
1
Share of China's trials
1.1%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 222025
ThemesAntibodies & diagnosisStandard immunotherapyThymus & thymectomy

Hospitals counted here

  1. Renji Hospital3
  2. Xinhua Hospital2
  3. Songjiang Hospital, Shanghai Jiao Tong University1
  4. Ruijin Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
1.1%Leads about 1 in 89 of China's research papers on Moyamoya New since 2021

Led 4 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 222025
ThemesImaging & blood flowRevascularisation surgeryStroke & bleeding outcomes

Hospitals counted here

  1. Ruijin Hospital2
  2. Shanghai General Hospital Counted in the group total1
  3. Renji Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
2.0%Leads about 1 in 50 of China's research papers on Wilson disease

Led 4 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
1
Share of China's trials
6.2%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 332025
ThemesGenetics (ATP7B)Diagnosis & copper testsLiver disease & transplant

Hospitals counted here

  1. Xinhua Hospital2
  2. Renji Hospital Counted in the group total1
  3. Shanghai General Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Biliary atresia

胆道闭锁
6.5%Leads about 1 in 15 of China's research papers on Biliary atresia ▼ from 16.5%

Led 14 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.8%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
4
Share of China's trials
20.0%
Share of the world's papers
1.8%
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 1120242025: 112025
ThemesDisease mechanismsScreening & diagnosisLiver transplant

Hospitals counted here

  1. Xinhua Hospital9
  2. Renji Hospital3
  3. Children's Hospital, Shanghai Jiao Tong University Counted in the group total1
  4. Shanghai Children's Medical Center Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
1.5%Leads about 1 in 66 of China's research papers on Anti-NMDA receptor encephalitis ▼ from 4.0%

Led 4 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Renji Hospital2
  2. Shanghai General Hospital1
  3. Ruijin Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
1.1%Leads about 1 in 90 of China's research papers on Idiopathic pulmonary fibrosis

Led 11 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
11
Trials it led
1
Share of China's trials
1.4%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 332025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shanghai Ninth People's Hospital4
  2. Shanghai Chest Hospital3
  3. Shanghai Sixth People's Hospital2
  4. Shanghai General Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Clinical, radiologic, and physiologic features of idiopathic pulmonary fibrosis (IPF) with and without emphysema.2022Expert review of respiratory medicine
  2. Plasma apolipoprotein E protein attenuates pulmonary fibrosis through LRP1 and PLAU dual receptor-mediated TGF-β/Smad inhibition.2026Journal of advanced research
  3. Exploring the role of PANoptosis in idiopathic pulmonary fibrosis based on scRNA-seq and bulk-seq.2025Clinical and experimental medicine
  4. Cross-species tropism of AAV.CPP.16 in the respiratory tract and its gene therapies against pulmonary fibrosis and viral infection.2025Cell reports. Medicine
  5. Diagnosis of early idiopathic pulmonary fibrosis: current status and future perspective.2025Respiratory research
Trials on ClinicalTrials.gov6
  1. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Lead sponsorPhase 2Start 2025-08
  2. A Trial of HRS-9813 in Healthy SubjectsCompletedNCT06821464Study sitePhase 1Start 2025-02
  3. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  4. A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06081621Study sitePhase 2Start 2023-12
  5. A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis SubjectsCompletedNCT05895565Study sitePhase 1Start 2023-05
  6. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Study sitePhase 2Start 2023-06

PubMed searchClinicalTrials.gov

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病
4.4%Leads about 1 in 23 of China's research papers on Lymphangioleiomyomatosis

Led 2 of 45 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (31.1%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Ruijin Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
1.8%Leads about 1 in 56 of China's research papers on Amyotrophic lateral sclerosis

Led 14 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
2
Share of China's trials
3.6%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 222025

Hospitals counted here

  1. Shanghai Sixth People's Hospital4
  2. Renji Hospital3
  3. Ruijin Hospital2
  4. Shanghai Mental Health Center1
  5. Xinhua Hospital1
  6. Shanghai General Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Spinal muscular atrophy

脊髓性肌萎缩症
0.0%Leads none of China's research papers on Spinal muscular atrophy

Led 0 of 55 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (29.1%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%
Trials on ClinicalTrials.gov2
  1. Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular AtrophyEnrolling by invitationNCT06888661Study siteEarly phase 1Start 2025-03
  2. A Clinical Study Evaluating the Safety and Efficacy of SKG0201 Injection in Patients With Spinal Muscular Atrophy Type 1Active, not recruitingNCT06191354Study siteN/AStart 2023-06

PubMed searchClinicalTrials.gov

Fabry disease

法布雷病
5.5%Leads about 1 in 18 of China's research papers on Fabry disease ▼ from 9.1%

Led 4 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.3%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Ruijin Hospital3
  2. Xinhua Hospital1
  3. Renji Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Pompe disease

庞贝病
0.0%Leads none of China's research papers on Pompe disease

Led 0 of 30 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.7%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
1.9%Leads about 1 in 53 of China's research papers on Duchenne muscular dystrophy ▼ from 6.1%

Led 4 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
2
Research papers it led
4
Trials it led
2
Share of China's trials
10.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 112025

Hospitals counted here

  1. Shanghai Ninth People's Hospital2
  2. Shanghai Children's Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
1.2%Leads about 1 in 82 of China's research papers on Behçet disease

Led 3 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Renji Hospital2
  2. Shanghai Ninth People's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Alport syndrome

Alport 综合征
1.7%Leads about 1 in 58 of China's research papers on Alport syndrome ▼ from 5.6%

Led 1 of 58 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
1
Research papers it led
1
Trials it led
2
Share of China's trials
33.3%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Ruijin Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
2.0%Leads about 1 in 49 of China's research papers on IgA nephropathy ▼ from 3.5%

Led 15 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
2
Research papers it led
15
Trials it led
8
Share of China's trials
6.8%
Share of the world's papers
0.9%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 332025

Hospitals counted here

  1. Renji Hospital6
  2. Ruijin Hospital4
  3. Shanghai Children's Medical Center3
  4. Xinhua Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial.2021Renal failureRCT
  2. Thickening of Glomerular Basement Membrane Is Associated with Long-Term Prognosis in Patients with IgA Nephropathy.2026Kidney360
  3. Effectiveness and safety of telitacicept in IgA nephropathy: a propensity score matching analysis with a 6-month follow-up.2025BMC nephrology
  4. IgA nephropathy and IgA vasculitis in a pediatric Crohn's disease patient with early IgA deposition in vascular walls of intestines.2025CEN case reports
  5. The beneficial effect of adding belimumab in severe and refractory IgA nephropathy: a case report.2025Pediatric nephrology (Berlin, Germany)
Trials on ClinicalTrials.gov6
  1. Efficacy and Safety of Telitacicept in IgANRecruitingNCT06654596Lead sponsorN/AStart 2024-12
  2. The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)RecruitingNCT04858724Lead sponsorStart 2020-12
  3. Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANRecruitingNCT07390123Study sitePhase 3Start 2026-04
  4. A Study of SHR-2173 in Participants With Primary IgA NephropathyRecruitingNCT07354932Study sitePhase 2Start 2026-03
  5. A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingNCT06963827Study sitePhase 3Start 2025-07
  6. Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological LesionsNot yet recruitingNCT07888335Lead sponsorPhase 4Start 2026-12

PubMed searchClinicalTrials.gov

Gaucher disease

戈谢病
6.7%Leads about 1 in 15 of China's research papers on Gaucher disease ▼ from 23.1%

Led 2 of 30 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.7%).

Run this PubMed search

Open trials led
1
Research papers it led
2
Trials it led
2
Share of China's trials
16.7%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Xinhua Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Niemann–Pick disease type C

尼曼-匹克病 C 型
6.2%Leads about 1 in 16 of China's research papers on Niemann–Pick disease type C New since 2021

Led 1 of 16 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.2%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
1
Share of China's trials
50.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Xinhua Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. Development and validation of a new genotype-phenotype correlation for Niemann-Pick disease type C1.2024Journal of inherited metabolic disease
Trials on ClinicalTrials.gov2
  1. Study of Lithium Carbonate to Treat Niemann-Pick Type C1 DiseaseStatus unknownNCT03201627Lead sponsorEarly phase 1Start 2017-07
  2. Safety and Efficacy of Miglustat in Chinese NPC PatientsCompletedNCT03910621Study sitePhase 4Start 2020-04

PubMed searchClinicalTrials.gov

Osteogenesis imperfecta

成骨不全症
8.1%Leads about 1 in 12 of China's research papers on Osteogenesis imperfecta ▲ from 6.2%

Led 8 of 99 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.0%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 2220242025: 112025

Hospitals counted here

  1. Shanghai Sixth People's Hospital7
  2. Shanghai Ninth People's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
6.3%Leads about 1 in 16 of China's research papers on Primary biliary cholangitis ▼ from 10.1%

Led 19 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
1
Research papers it led
19
Trials it led
3
Share of China's trials
6.0%
Share of the world's papers
1.9%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 222025

Hospitals counted here

  1. Renji Hospital17
  2. Xinhua Hospital1
  3. Shanghai Sixth People's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. B cells drive CCR5+CD4+ tissue-resident memory T-cell cytotoxicity via IL-15Rα-IL-15 signaling in primary biliary cholangitis.2025Journal of hepatology
  2. Gut Microbiota-Derived Butyrate Induces Epigenetic and Metabolic Reprogramming in Myeloid-Derived Suppressor Cells to Alleviate Primary Biliary Cholangitis.2024Gastroenterology
  3. Reply to: "ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort".2024Journal of hepatology
  4. NUDT1 promotes the accumulation and longevity of CD103+ TRM cells in primary biliary cholangitis.2022Journal of hepatology
  5. Gut microbiome pattern impacts treatment response in primary biliary cholangitis.2025Med (New York, N.Y.)
Trials on ClinicalTrials.gov6
  1. Biochemical Response and Clinical Outcomes in Patients With PBCRecruitingNCT07449793Lead sponsorStart 2026-02
  2. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12
  3. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingNCT06051617Study sitePhase 3Start 2023-09
  4. The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe ItchingNot yet recruitingNCT07678645Lead sponsorPhase 2Start 2026-06
  5. Early Identification of Myocardial Impairment in PBCCompletedNCT03545672Lead sponsorStart 2017-10
  6. A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic InjuryCompletedNCT06888115Study sitePhase 1Start 2025-03

PubMed searchClinicalTrials.gov

Primary sclerosing cholangitis

原发性硬化性胆管炎
6.0%Leads about 1 in 17 of China's research papers on Primary sclerosing cholangitis ▼ from 12.2%

Led 6 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.0%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
2
Share of China's trials
33.3%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Renji Hospital5
  2. Shanghai Sixth People's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Congenital diaphragmatic hernia

先天性膈疝
11.7%Leads about 1 in 9 of China's research papers on Congenital diaphragmatic hernia ▲ from 3.2%

Led 7 of 60 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (18.3%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Xinhua Hospital3
  2. Shanghai Children's Medical Center2
  3. Shanghai Children's Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
5.0%Leads about 1 in 20 of China's research papers on Hirschsprung disease ▼ from 7.2%

Led 8 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.1%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Xinhua Hospital6
  2. Shanghai Children's Medical Center2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症
10.7%Leads about 1 in 9 of China's research papers on Inherited epidermolysis bullosa ▼ from 16.7%

Led 6 of 56 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.5%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 2220222023: 2220232024: 1120242025: 002025

Hospitals counted here

  1. Xinhua Hospital4
  2. Shanghai Children's Medical Center1
  3. Shanghai Ninth People's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hereditary angioedema

遗传性血管性水肿
6.2%Leads about 1 in 16 of China's research papers on Hereditary angioedema New since 2021

Led 2 of 32 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (31.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Renji Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Familial adenomatous polyposis

家族性腺瘤性息肉病
3.4%Leads about 1 in 29 of China's research papers on Familial adenomatous polyposis ▲ from 2.0%

Led 2 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Ruijin Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Leber hereditary optic neuropathy

Leber 遗传性视神经病变
5.8%Leads about 1 in 17 of China's research papers on Leber hereditary optic neuropathy New since 2021

Led 3 of 52 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (21.1%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

Hospitals counted here

  1. Shanghai General Hospital2
  2. Shanghai Ninth People's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov